{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T08:53:26Z","timestamp":1789030406147,"version":"build-2803163510"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T00:00:00Z","timestamp":1767830400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009954","name":"Taiho Pharmaceutical","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009954","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006293","name":"American Society of Clinical Oncology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006293","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["eClinicalMedicine"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.eclinm.2026.103768","type":"journal-article","created":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T12:40:59Z","timestamp":1769690459000},"page":"103768","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Solvent-based or nab-paclitaxel plus ramucirumab for pretreated gastric cancer with peritoneal dissemination and prespecified biomarker analysis (P-SELECT\/WJOG10617G): a randomised phase 2 trial in Japan"],"prefix":"10.1016","volume":"92","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4536-7781","authenticated-orcid":false,"given":"Kenro","family":"Hirata","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuo","family":"Hamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirokazu","family":"Shoji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Hara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6189-4851","authenticated-orcid":false,"given":"Chihiro","family":"Kondoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hisateru","family":"Yasui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Kajiwara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eishi","family":"Baba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takayuki","family":"Ando","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naotoshi","family":"Sugimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hisato","family":"Kawakami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroo","family":"Katsuya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michitaka","family":"Nagase","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiyuki","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenichi","family":"Yoshimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiko","family":"Ando","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiyo K.","family":"Imamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kentaro","family":"Yamazaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuichi","family":"Hironaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kei","family":"Muro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eclinm.2026.103768_bib1","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.eclinm.2026.103768_bib2","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/S1470-2045(08)70035-4","article-title":"S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase 2I trial","volume":"9","author":"Koizumi","year":"2008","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eclinm.2026.103768_bib3","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1093\/annonc\/mdp464","article-title":"Phase 2 study of oxaliplatin plus S-1 as first-line treatment for advanced gastric cancer (G-SOX study)","volume":"21","author":"Koizumi","year":"2010","journal-title":"Ann Oncol"},{"key":"10.1016\/j.eclinm.2026.103768_bib4","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S0140-6736(21)00797-2","article-title":"First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial","volume":"398","author":"Janjigian","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.eclinm.2026.103768_bib5","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1016\/S1470-2045(23)00515-6","article-title":"Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial","volume":"24","author":"Rha","year":"2023","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eclinm.2026.103768_bib6","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/S0140-6736(10)61121-X","article-title":"Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial","volume":"376","author":"Bang","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.eclinm.2026.103768_bib7","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1038\/s41591-023-02465-7","article-title":"Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial","volume":"29","author":"Shah","year":"2023","journal-title":"Nat Med"},{"key":"10.1016\/j.eclinm.2026.103768_bib8","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1016\/S0140-6736(23)00620-7","article-title":"Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial","volume":"401","author":"Shitara","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.eclinm.2026.103768_bib9","doi-asserted-by":"crossref","first-page":"4882","DOI":"10.3390\/jcm10214882","article-title":"The burden of peritoneal metastases from gastric cancer: a systematic review on the incidence, risk factors and survival","volume":"10","author":"Rijken","year":"2021","journal-title":"J Clin Med"},{"key":"10.1016\/j.eclinm.2026.103768_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2025.103109","article-title":"The prognostic value of peritoneal metastases in patients with gastric cancer: a nationwide population-based study","volume":"81","author":"Guchelaar","year":"2025","journal-title":"eClinicalMedicine"},{"key":"10.1016\/j.eclinm.2026.103768_bib11","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1016\/S1470-2045(14)70420-6","article-title":"Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial","volume":"15","author":"Wilke","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eclinm.2026.103768_bib12","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1517\/14656566.7.8.1041","article-title":"Albumin-bound paclitaxel: a next-generation taxane","volume":"7","author":"Gradishar","year":"2006","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.eclinm.2026.103768_bib13","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/S2468-1253(16)30219-9","article-title":"Nab-paclitaxel versus solvent-based paclitaxel in patients with previously treated advanced gastric cancer (ABSOLUTE): an open-label, randomised, non-inferiority, phase 3 trial","volume":"2","author":"Shitara","year":"2017","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.eclinm.2026.103768_bib14","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s10120-018-0838-6","article-title":"Peritoneal metastasis as a predictive factor for nab-paclitaxel in patients with pretreated advanced gastric cancer: an exploratory analysis of the phase 2I ABSOLUTE trial","volume":"22","author":"Takashima","year":"2019","journal-title":"Gastric Cancer"},{"key":"10.1016\/j.eclinm.2026.103768_bib15","doi-asserted-by":"crossref","first-page":"4200","DOI":"10.1158\/1078-0432.CCR-07-4592","article-title":"Randomized crossover pharmacokinetic study of solvent-based paclitaxel and nab-paclitaxel","volume":"14","author":"Gardner","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.eclinm.2026.103768_bib16","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.ejca.2017.11.032","article-title":"A phase 2 study of nab-paclitaxel in combination with ramucirumab in patients with previously treated advanced gastric cancer","volume":"91","author":"Bando","year":"2018","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.eclinm.2026.103768_bib17","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1186\/s12885-020-07047-1","volume":"20","author":"Hirata","year":"2020","journal-title":"BMC Cancer"},{"key":"10.1016\/j.eclinm.2026.103768_bib18","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.ctrv.2016.09.004","article-title":"Nab-paclitaxel for the treatment of triple-negative breast cancer: rationale, clinical data and future perspectives","volume":"50","author":"Schettini","year":"2016","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.eclinm.2026.103768_bib19","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/S0306-3623(97)89716-9","article-title":"The transport and binding of Taxol","volume":"29","author":"Parekh","year":"1997","journal-title":"Gen Pharmacol"},{"key":"10.1016\/j.eclinm.2026.103768_bib20","series-title":"Common Terminology Criteria for Adverse Events (CTCAE)","year":"2009"},{"key":"10.1016\/j.eclinm.2026.103768_bib21","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1136\/ijgc-00009577-200311000-00003","article-title":"Psychometric evaluation of the Functional Assessment of Cancer Therapy\/Gynecologic Oncology Group\u2013Neurotoxicity (FACT\/GOG-Ntx) questionnaire for patients receiving systemic chemotherapy","volume":"13","author":"Calhoun","year":"2003","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.eclinm.2026.103768_bib22","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.eclinm.2026.103768_bib23","doi-asserted-by":"crossref","first-page":"4811","DOI":"10.1158\/1078-0432.CCR-14-3222","article-title":"SPARC expression did not predict efficacy of nab-paclitaxel plus gemcitabine or gemcitabine alone for metastatic pancreatic cancer in an exploratory analysis of the phase 2I MPACT trial","volume":"21","author":"Hidalgo","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.eclinm.2026.103768_bib24","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1634\/theoncologist.2013-0306","article-title":"Determination of prognostic factors in Japanese patients with advanced gastric cancer using the data from a randomized controlled trial, Japan Clinical Oncology Group 9912","volume":"19","author":"Takahari","year":"2014","journal-title":"Oncologist"},{"key":"10.1016\/j.eclinm.2026.103768_bib25","doi-asserted-by":"crossref","first-page":"148","DOI":"10.21037\/jgo.2017.01.10","article-title":"Prognostic value of diffuse versus intestinal histotype in patients with gastric cancer: a systematic review and meta-analysis","volume":"8","author":"Petrelli","year":"2017","journal-title":"J Gastrointest Oncol"},{"key":"10.1016\/j.eclinm.2026.103768_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2021.100234","article-title":"A novel clinical prognostic index for patients with advanced gastric cancer: possible contribution to the continuum of care","volume":"6","author":"Shimozaki","year":"2021","journal-title":"ESMO Open"},{"key":"10.1016\/j.eclinm.2026.103768_bib27","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/978-1-4613-1247-5_23","article-title":"Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis","volume":"82","author":"Jacquet","year":"1996","journal-title":"Cancer Treat Res"},{"key":"10.1016\/j.eclinm.2026.103768_bib28","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1158\/1535-7163.MCT-16-0895","article-title":"Exposure\u2013response analyses of ramucirumab from two randomized, phase 2I trials of second-line treatment for advanced gastric or gastroesophageal junction cancer","volume":"16","author":"Tabernero","year":"2017","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.eclinm.2026.103768_bib29","first-page":"54","article-title":"Exposure\u2013response relationship and safety of ramucirumab in patients with metastatic colorectal cancer from the RAISE phase 2I study","volume":"22","author":"Tabernero","year":"2023","journal-title":"Clin Colorectal Cancer"},{"key":"10.1016\/j.eclinm.2026.103768_bib30","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/s00280-022-04447-x","article-title":"RELAY, ramucirumab plus erlotinib versus placebo plus erlotinib in untreated EGFR-mutated metastatic non-small cell lung cancer: exposure\u2013response relationship","volume":"90","author":"Nakagawa","year":"2022","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.eclinm.2026.103768_bib31","doi-asserted-by":"crossref","first-page":"3182","DOI":"10.1111\/bcp.15233","article-title":"Exposure\u2013response relationship of ramucirumab in RANGE, a randomized phase 2I trial in advanced urothelial carcinoma refractory to platinum therapy","volume":"88","author":"de Wit","year":"2022","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.eclinm.2026.103768_bib32","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1152\/physrev.00038.2010","article-title":"Normalization of the vasculature for treatment of cancer and other diseases","volume":"91","author":"Goel","year":"2011","journal-title":"Physiol Rev"},{"key":"10.1016\/j.eclinm.2026.103768_bib33","doi-asserted-by":"crossref","first-page":"5925","DOI":"10.1158\/0008-5472.CAN-17-0604","article-title":"Caveolae-mediated endocytosis is critical for albumin cellular uptake and response to albumin-bound chemotherapy","volume":"77","author":"Chatterjee","year":"2017","journal-title":"Cancer Res"}],"container-title":["eClinicalMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537026000155?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537026000155?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T20:30:16Z","timestamp":1784579416000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589537026000155"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":33,"alternative-id":["S2589537026000155"],"URL":"https:\/\/doi.org\/10.1016\/j.eclinm.2026.103768","relation":{},"ISSN":["2589-5370"],"issn-type":[{"value":"2589-5370","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Solvent-based or nab-paclitaxel plus ramucirumab for pretreated gastric cancer with peritoneal dissemination and prespecified biomarker analysis (P-SELECT\/WJOG10617G): a randomised phase 2 trial in Japan","name":"articletitle","label":"Article Title"},{"value":"eClinicalMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eclinm.2026.103768","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"103768"}}